• Image 01
  • Stimulates polyamine uptake system
  • Image 01
  • Image 01
  • Image 01
  • Image 01
First

First-in-class Oncology Product

Polyamine Blocker Therapy (PaBT™) removes critical substances (polyamines) from the cancer cell.

Animal

Animal Proof-of-concept

PaBT™ demonstrates robust activity in advanced mouse models and in spontaneous oral tumors in housecats.

Unique

Unique Mechanism of Action

Removal of polyamines from cancer cells unleashes immune system to destroy tumors.

Opportunity

Business Opportunity

By acting as an "Immune Checkpoint Blocker" Aminex's PaBT™ approach has potential to be combined with other promising cancer                                   immunotherapies.

Latest Achievements

  • Publication of collaborative research highlighting the immunosuppressive role of polyamine metabolites, and the ability of PaBT to overcome this immune block. (Polyamine-Blocking Therapy Reverses Immunosuppression in the Tumor Microenvironment. Hayes, C.S.; Shicora, A.C.; Keough, M.P.; Snook, A.E.; Burns, M.R.; Gilmour, S.K. Cancer Immunology Research, 2014, 2(3), 274-85 (see http://www.ncbi.nlm.nih.gov/pubmed/24778323).
  • Publication of collaborative research results demonstrating potential for use Aminex's PaBT approach for treatment of neuroblastoma (AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithing decarboxylase and polyamine transport. Samal, K.; Zhao, P.; Kendzicky, A.; Yco, L.P.; McClung, H.; Gerner, E.; Burns, M.; Bachmann, A.S.; Sholler, G. Int. J. Cancer, 2013, 133(6), 1323-33 (see http://www.ncbi.nlm.nih.gov/pubmed/23457004).
  • Results from Phase I/II trial using PaBT™ for oral cancers in house cats has been published (see Skorupski, K. A., O'Brien, T. G., Guerrero, T., Rodriguez, C. O., and Burns, M. R. Phase I/II clinical trial of 2-difluoromethylornithine (DFMO) and a novel polyamine transport inhibitor for feline oral squamous cell carcinoma., Vet Comp Oncol. 2011, 9(4), 275-82 (see http://www.ncbi.nlm.nih.gov/pubmed/22077408).
  • Development achievements including custom manufacturing of AMXT 1501, formulation and delivery testing and bioanalytical analysis method development have been achieved.

Read More

News

  • Dr. Mark R. Burns, President & CEO spoke at the Life Sciences Innovation Northwest (LSINW) Conference, held July 10, 2013 in Seattle (Washington Convention Center).
  • Dr. Mark R. Burns, President & CEO presented Aminex's PaBT approach at the BIO 2013 Conference in Chicago. He spoke at the BIO Business Forum at 10:45am on Wednesday, April 24, 2013 in the Chicago Blackhawks Room. 
  • Publication of collaborative research results demonstrating potential for use Aminex's PaBT approach for treatment of neuroblastoma (Samal, K.; Zhao, P.; Kendzicky, A.; Yco, L.P.; McClung, H.; Gerner, E.; Burns, M.; Bachmann, A.S.; Sholler, G. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithing decarboxylase and polyamine transport (see abstract here). Accepted for publication in International Journal of Cancer (DOI: 10.1002/ijc.28139).
  • Reissue of Aminex's US Patent has been awarded.

Read More